Sangamo Therapeutics (SGMO) Earning Somewhat Favorable News Coverage, Study Shows
Media coverage about Sangamo Therapeutics (NASDAQ:SGMO) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sangamo Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.5900614764766 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Zacks: Analysts Expect Sangamo Therapeutics, Inc. (SGMO) to Announce -$0.18 Earnings Per Share (americanbankingnews.com)
- Technical Indicators should not be overlooked on Sangamo Therapeutics, Inc. (SGMO) – Wall Street Morning (wallstreetmorning.com)
- Healthcare stock in Focus- Sangamo Therapeutics, Inc. (SGMO) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Sangamo Therapeutics Inc (NASDAQ:SGMO): Has Recent Earnings Growth Beaten Long-Term Trend? (finance.yahoo.com)
A number of brokerages have issued reports on SGMO. Wells Fargo & Co reiterated an “outperform” rating and set a $30.00 price objective (up previously from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. Jefferies Group reiterated a “buy” rating and set a $18.00 price objective on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price objective for the company in a research note on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Wednesday, November 15th. Finally, Barclays began coverage on Sangamo Therapeutics in a research note on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $17.83.
Sangamo Therapeutics (SGMO) opened at $16.95 on Wednesday. The stock has a market capitalization of $1,430.00, a price-to-earnings ratio of -24.57 and a beta of 3.15. Sangamo Therapeutics has a one year low of $2.85 and a one year high of $18.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. During the same quarter in the previous year, the business earned ($0.27) earnings per share. The firm’s quarterly revenue was up 333.0% compared to the same quarter last year. equities research analysts forecast that Sangamo Therapeutics will post -0.73 EPS for the current fiscal year.
In other news, VP Curt A. Herberts III sold 11,803 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $18.00, for a total value of $212,454.00. Following the completion of the transaction, the vice president now owns 27,636 shares in the company, valued at $497,448. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $16.24, for a total value of $81,200.00. Following the completion of the transaction, the vice president now owns 5,000 shares of the company’s stock, valued at approximately $81,200. The disclosure for this sale can be found here. Insiders sold 53,433 shares of company stock valued at $863,996 in the last 90 days. Company insiders own 5.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://theolympiareport.com/2017/12/27/sangamo-therapeutics-sgmo-earning-somewhat-favorable-news-coverage-study-shows.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.